搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
FiercePharma
1 小时
Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new ...
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
JD Supra
2 小时
The GLP-1 Saga Continues: FDA Ends the Tirzepatide Shortage: Frequently Asked Questions
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
manilatimes
2 小时
Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer
Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...
20 小时
This Wegovy user spent $5,000 on a new wardrobe after losing 80 pounds - and she's not alone
Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.
WISN 12 NEWS
22 小时
Your phone may not be the best alarm clock if you want a good night of sleep
If you are getting enough sleep at night consistently but are still not sleeping well or waking up feeling rested, it may be ...
1 天
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
1 天
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose ...
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...
2 天
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One ...
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
2 天
Why Eli Lilly Stock Topped the Market Today
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
MM&M
2 天
Novo Nordisk’s amycretin cuts weight by 22% in early obesity trial
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
2 天
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
2 天
Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈